MedTrace Logo

Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

NCT02968394 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-11-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.

Conditions

  • Allergy
  • Bee Venom
  • Immunotherapy
  • Omalizumab

Interventions

DRUG

omalizumab

Sponsors & Collaborators

  • The University Clinic of Pulmonary and Allergic Diseases Golnik

    lead OTHER

Principal Investigators

  • Mitja Košnik, MD, PhD · University Clinic of Pulmonary and Allergic Diseases Golnik

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2017-03-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02968394 on ClinicalTrials.gov